The Effects Of Hepatocyte Growth Factor Gene Transfection In Reduction Of Hyperkinetic Pulmonary Artery Hypertension In A Rabbit Model

Background: Hyperkinetic pulmonary hypertension(HGF) is a common complication of congenital heart disease(CHD) with left to right shunt, which has an important effect on achievement ratio of surgical correction and long term survival of patients with CHD. Recent studies have demonstrated that increased pulmonary blood flow secondary to congenital heart disease produces increases in vascular shear stress, which results in profound effects on vascular endothelial cell. Under normal conditions, the endothelial cell tightly regulates pulmonary vascular tone and control smooth muscle cell proliferation, maintains the pulmonary vasculature in a low pressure state. Endothelial dysfunction results in exaggerated vasoconstriction and smooth muscle of small pulmonary arteries hypertrophy and proliferation, causes lumen stenosis and progressive obliteration of the pulmonary vascular bed, leading to pulmonary vascular resistance increase and pulmonary hypertension.Because of the thickening of pulmonary arterial wall and smooth muscle fibrosis, there is no ideal therapeutic effect using traditional approaches to reverse the advanced stage of pulmonary hypertension. At present, therapeutic angiogensis is focused on some reasch domain, especially ischemic dieases. The treatment is to improve perfusion of tissues or organs and reduce vascular resistance by inducing angiogenesis.